3 recruiting, 1 active not recruiting, 1 not yet recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Recurrent WHO Grade 4 Glioma: new trials by email Literature Review of Recurrent WHO Grade 4 Glioma trials Research Report on Recurrent WHO Grade 4 Glioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 30 | 2026-12-04 | 2026-06-12 |
| Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas Anti-GARP Chimeric Antigen Receptor-T Cells, Biospecimen Collection, Chest Radiography - Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 30 | 2025-05-21 | 2026-05-08 |
| Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma Bevacizumab, Biospecimen Collection, Computed Tomography - Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 134 | 2024-10-02 | 2024-11-19 |
| Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration - Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma | Phase 1 | Recruiting | Northwestern University | 22 | 2024-07-23 | 2026-09-09 |
| Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging - Recurrent Glioma, Recurrent WHO Grade 2 Glioma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2024-01-04 | 2026-10-15 |
Glioblastoma (3) · Glioma (2) · Gliosarcoma (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neoplasms, Neuroepithelial (5) · Neuroectodermal Tumors (5) · Astrocytoma (3) · Glioma (3)
Magnetic Resonance Spectroscopy (5) · Specimen Handling (5) · X-Rays (2) · 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (1) · Actinium (1) · Bevacizumab (1) · Blood Component Removal (1) · Disulfides (1) · Immunoglobulin G (1) · Photons (1) · Radiation (1) · Radiation Dose Hypofractionation (1) · Surgical Procedures, Operative (1) · Temozolomide (1) · Tomography, Optical Coherence (1)
National Cancer Institute (NCI) (2) · Academic and Community Cancer Research United (1) · Northwestern University (1) · Ohio State University Comprehensive Cancer Center (1)
United States (4)
James B Elder, MD (1) · Jian L Campian (1) · Karan Dixit, MD (1) · Megan Mantica (1)
P30CA015083 (1), P30CA060553 (1), UM1CA186644 (1), UM1CA186690 (1)